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ANTINOCICEPTIVE EFFECTS OF BOTULINUM TOXIN 
TYPE-A IN PAIN AND HEADACHES TREATMENT
Maja Relja
Department of neurology, Medical school University of Zagreb, Zagreb, Croatia
Summary
Since its development for clinical use in 1980s botulinum toxin, the most potent 
biological toxin known to man has become a useful drug in various field of medicine. 
It was initially used to treat neurological disorders characterized by excessive muscle 
contractions. Since many patients report alleviation of pain before the muscle relaxing 
effect of botulinum toxin type-A has started, a direct analgesic action of Botulinum toxin 
has been discussed. There have been a number of recent investigations concerning the 
efficacy of botulinum toxin type-A applications for treatment of headache and chronic 
pain. Most of the known effect of botulinum toxin has been attributed to its ability to 
inhibit the release of acetylcholine from cholinergic nerve terminal. However, this effect 
alone does not explain the apparent antinociceptive effect of botulinum toxin. Other pe-
ripheral and central neurogenic effect should be considered. Current data suggest that 
Botulinum toxin is safe and effective in headache and pain treatment if used in specialist 
centres by experienced doctors. 
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IntroductIon
Botulinum toxin type-A (BTX-A), the most potent of poisons, is one of se-
ven distinct serotypes (A to G) of neurotoxin produced by the anaerobic bac-
terium Clostridium Botulinum. When injected into muscles, BTX-A binds to the 
presynaptic nerve terminal, becomes internalized, and blocks the release of the 
neurotransmitter acetylcholine (ACh) by cleaving the synaptosomal-associated 
protein (SNAP-25) [1]. This action causes chemical denervation at neuromus-
cular junction, thereby inhibiting muscle contractions and producing muscle 
relaxation or weakness [2]. It has been used since the mid 1980s to treat patients 
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suffering from uncontrolled muscle activity and/or increased muscle tone. First, 
local injections of BTX-A were successfully used in the management of dystonia 
– an extrapyramidal condition involving uncontrolled muscle over-activity. Se-
cond, BTX-A was used in the treatment of limb spasticity and more particularly 
in juvenile cerebral palsy. The weakening effect is not seen for approximately 
10 days and the effects are temporary because the presynaptic terminal sprouts 
new accessory terminals and the main terminal recovers its ability to release 
ACh.  But the number of therapeutic uses of botulinum toxin has grown consi-
derably over the past decade. Nowadays BTX-A is also used to treat disorders of 
the smooth muscle systems, such as anal fissure, or disorders like hyperhidro-
sis and other secretory disorders. All this clinical application of BTX-A can be 
clearly associated with temporary chemodenervation of peripheral somatic or 
vegetative cholinergic nerves.  
clInIcal ExpErIEncE of Btx-a antInocIcEptIvE actIon
There has been increasing clinical evidence that BTX-A might also have anal-
gesic properties. It has been generally recognized the marked analgesic effect of 
BTX-A when used in the treatment of pain associated with dystonia and spasti-
city.1 The clinical observation confirmed that the pain relief experienced may 
be considerably more marked than the degree of motor benefit obtained and 
may lasted beyond the period of muscle relaxation. Several studies suggest that 
a direct antinociceptive affect distinct from reduction in muscle spasm may be 
involved. We performed the first study investigating the effect of tree different 
doses of BTX-A on pain in cervical dystonia. The major benefit of BTX-A trea-
tment of pain reduction compared to dystonia improvement was the duration of 
action and the lower effective doses. In addition, pain relief occurs before muscle 
relaxation can be observed. Our results suggest that a direct antinociceptive af-
fect distinct from reduction in muscle over activity and spasm may be involved 
[3]. Moreover, BTX-A also seems to have analgesic properties in primary pain 
syndromes such as chronic tension type headache, migraine, neuropatic pain, 
certain types of myofascial pain and low back pain without obvious correlation 
to muscular hyper contractility. Therefore, clinical observations suggest an anti-
nociceptive action independent of its neuromuscular junction-blocking effect.
HEadacHE
Headache is one of the most common neurological symptoms in clinical 
practice. The primary headache disorders consist of tension-type headache, mi-
graine, and cluster headache. Tension-type headache (TTH) and migraine are 
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extremely common cause of chronic pain in clinical practice. The lifetime preva-
lence of headache approaches 99% in women and 93% in men [4].
The current therapeutic approaches to tension-type headache and migraine 
consist of acute and/or prophylactic therapy that offer relief for many patients 
but are often unsatisfactory for many others. Therefore, headache patients still 
represent a group of patients with unmet treatment needs.
tEnsIon typE HEadacHE
Tension-type headache is the most common primary headache type that is 
not associated with a serious underlying disease. Duration of attacks can vary 
from a few hours to several days and the intensity of pain is usually less seve-
re than in the migraine, with no accompanying symptoms. TTH is classically 
described as aching, tenderness and band-like pain surrounding the head.  The 
episodical variant prevailing in more than one third of the population, while 
chronic TTH, when attacks occur more frequently than 15 days per month, is 
found in about 3%. TTH is classically described as aching, tenderness and band-
like pain surrounding the head. Current therapies are still unsatisfactory becau-
se pathophysiology is not well understood. Muscular causes accounting for the 
TTH are still the most commonly debated. Since the involvement of pricranial 
muscles over-activity may contribute to TTH, we were the first who investigated 
the effectiveness of BTX-A therapy in chronic TTH [5-7]. In addition to short-
term studies we performed the first prospective long-term study of 15 months 
duration where BTX-A injections were found to be an effective and safe prop-
hylactic treatment for TTH patients for whom standard therapy has failed [8].
Chronic TTH should not be treated for long time by analgesics because of the 
risk of overuse. According to our investigations and published results, BTX-A 
treatment should be considered when the patients have verified chronic TTH, 
and after the preventive drug treatment has failed [7].
MIgraInE
Migraine is characterised by unilateral, pulsating pain, aggravation by rou-
tine physical activity, and association with nausea, photophobia and phonopho-
bia. With a lifetime prevalence of approximately 13% to 18% in women and 8% to 
14%i in men, migraine is the second most frequently occuring form of headache 
after TTH [4]. Contrary to TTH, the effect of migraine on quality of life is signi-
ficant. All migraine patients experienced functional impairment and more than 
half required bedrest with significant loss of working days. 
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Although the eraliest modern theory on the pathophysiology of migraine 
was the ‘vascular’ theory current opinion show that sensory stimuly can lead 
to a permanent sensory overflow of the central nervous system with the result 
in hyperactivity of the sensory brain stem nuclei. BTX-A can interfere at various 
point, but it is clear that antinociceptive effects of BTX-A in migraine could not 
be explained by ‘clasic’ anticholinergic denervation. 
The first evidence for the efficacy of BTX-A in migraine was reported as sur-
prising side effect in patients primary treated for hypefunctional facial lines by 
otorinolaringoligist Wiliam Binder [1]. Until recently the efficacy of BTX-A in 
preventing migraine attacks remains controversial. Contrary to the first mul-
ticener double-blind, placebo-controled study with 954 patients screened and 
495 randomized, second big multicenter study with 705 patients randomized 
confirms that BTX-A is effective for the prophylaxis of patients with chronic 
migraine [19,10]. Investigating the clasic migraine symptoms that would diffe-
rentiate responders from non-responders to prophylactic BTX-A tretament in 
episodic migraine we have shown for the first time that patients with cutaneous 
allodynia are highly associated with significnat prevention of migraine attacks 
using BTX-A treatment [11]. Comparative study with standard migraine therapy 
is still needed. 
nEuropatIc paIn
Neuropathic pain is associated with injury to the peripheral and/or central 
nervous system. Conditions such as post herpetic neuralgia, spinal cord injury 
and diabetic neuropathy are examples of neuropathic pain [12]. Contrary to he-
adaches and pain associated with increased muscle tone there were only a limi-
ted number of case reports suggesting that BTX-might be useful in pain which 
is not associated with a muscle spasm. Our experimental data showed effective-
ness of BTX-A in experimental neuropathic pain in classical model of surgical 
neuropathy as well as in diabetic neuropathy [13]. Knowing these results we per-
formed the first clinical study in diabetic neuropathy patients. In a prospective 
double-blind study we showed for the first time the efficacy and safety of BTX-A 
for the treatment of painful diabetic neuropathy [14]. More results today indicate 
clear benefit of BTX-A therapy for the treatment of neuropathic pain disorders. 
There is need for more studies in nociceptive and neuropathic disorders to better 
define BTX-A role as analgesics. 
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conclusIon
BTX-A is known to alleviate pain when it is used to treat certain diseases 
associated with muscle over activity. But the mechanism for pain relief is not 
completely understood. Clinical observations suggest an antinociceptive action 
of BTX-A independent of its neuromuscular junction-blocking effects. Thus me-
chanism of action, its duration, doses and application points are still awaiting 
carefully designed preclinical and clinical experiments. Thus, the current use of 
BTX-A headache and chronic pain disorders is only justified after all standard 
therapeutic procedures have been exhausted and only following evaluation in 
specialist centres. Its use requires extensive experience and practice in its appli-
cation with precise functional-anatomical knowledge.  
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Sažetak
Antinociceptivni učinak botulinum toksina tip-A u terapiji boli i glavobolje
Nakon razvoja botulinum toksina za kliničku primjenu 80-tih godina, ovaj za čovjeka najpo-
tentniji biološki otrov našao je primjenu u raznim granama medicine. Prva upotreba botulinum 
toksina bila je u neurološkim poremećajima karakteriziranim mišićnim spazmom i nekontrolira-
nim kontrakcijama poput distonije. Zapaženi učinak na smanjenje boli prije pojave mišićne relak-
sacije ukazao je na direktni analgetski učinak botulinum toksina na patogenezu boli. Javljaju se 
zatim brojna klinička zapažanja o učinkovitosti botulinum toksina u liječenju glavobolje i kronič-
ne boli. Većina poznatih učinaka botulinum toksina na relaksaciju mišića pripisuje se učinku na 
otpuštanje acetilkolina na neuromuskularnoj sinapsi. Kako se ovim djelovanjem ne može obja-
sniti njegov antinociceptivni učinak brojni periferni i centralni mehanizmi djelovanja botulinum 
toksina se istražuju. Sadašnji rezultati kliničke primjene ukazuju da je botulinum toksin siguran i 
djelotvoran lijek u liječenju glavobolje i nekih oblika kronične boli otpornih na standardne oblike 
liječenja, ukoliko se primjenjuje u specijaliziranom centru od strane iskusnih liječnika.
Ključne riječi: botulinum toksin; distonija; bol; tenzijska glavobolja; migrena.
